Akari Therapeutics (AKTX) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Akari Therapeutics
Is Akari Therapeutics a buy right now? The alternative data says hold. This AKTX stock analysis is built on the 25+ alternative data signals AltIndex tracks on Akari Therapeutics every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 44/100: a Hold. The stock trades at $7.18 with a $13M market cap.
The data leans positive over the past 90 days — web traffic up 18.2% to 4K monthly visits, and sentiment up 187.9% to 95/100 — but the move hasn’t been broad enough to lift AKTX into buy territory yet.
AKTX’s broader alt-data profile also covers headcount (15 employees, according to LinkedIn), and Reddit mentions (1 a day). Every signal links to its own page with full history, the AKTX technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on AKTX is just below.
Akari Therapeutics AI Stock Analysis
Akari Therapeutics is a biopharmaceutical company focused on developing therapies for rare and orphan diseases. The company's main product pipeline targets various autoimmune and inflammatory diseases, with a focus on rare conditions that have significant unmet medical needs.
Analysis generated August 2, 2026.
Recent Akari Therapeutics Stock Alerts
|
Akari Therapeutics | August 12 Price is down by -8.2% in the last 24h. |
|
Akari Therapeutics | August 10 Price is up by 8.6% in the last 24h. |
|
Akari Therapeutics | August 7 Price is down by -6.3% in the last 24h. |
|
Akari Therapeutics | August 6 Price is up by 6.7% in the last 24h. |
Akari Therapeutics Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 4K | 18.2% | |
| LinkedIn Employees | 15 | N/A | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 95 | 187.9% | |
| Reddit Mentions | 1 | 0% | |
| X Mentions | 3 | N/A | |
| Stocktwits Mentions | 3 | 57.1% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 9K | 5.3% |
About Akari Therapeutics (AKTX)
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
| Price | $7.18 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $13M |
| Year Range | $3 – $45 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Akari Therapeutics News
View more →
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC InnovationAugust 4 - GlobeNewswire |
|
Akari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology OpportunityJuly 22 - GlobeNewswire |
|
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk TherapeuticsJuly 21 - GlobeNewswire |
|
Akari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory MilestonesJune 29 - GlobeNewswire |
|
Akari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari’s Differentiated PH1 Payload Platform Following ASCO 2026June 4 - GlobeNewswire |
Akari Therapeutics Earnings & Financial Performance
View all earnings →Akari Therapeutics Insider Trading Activity
View all →| Neal James R filed to sell 2,473 shares at $0.0. Dec 16 '25 |
| Neal James R filed to sell 3,093 shares at $0.0. Dec 16 '25 |
| Bazemore Robert B filed to sell 30,932 shares at $0.0. Dec 16 '25 |
| Farag Kameel D. filed to sell 24,745 shares at $0.0. Dec 16 '25 |
| Bazemore Robert B filed to sell 123,731 shares at $0.0. Dec 16 '25 |
Akari Therapeutics Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Akari Therapeutics
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Bionano GenomicsBNGO |
$1.20 0.8% | $13M | 30 |
 |
AEON BiopharmaAEON |
$0.28 0.7% | $13M | 50 |
 |
OSR HoldingsOSRH |
$0.29 25.1% | $14M | 54 |
 |
Zivo BioscienceZIVO |
$4.29 0.0% | $15M | 44 |
 |
Kala PharmaceuticalsKALA |
$0.88 4.6% | $15M | 44 |
Explore Akari Therapeutics Data
Frequently Asked Questions: Akari Therapeutics (AKTX)
Akari Therapeutics has an AltIndex AI Score of 44/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
44/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Akari Therapeutics (AKTX) stock is $7.18 with a market cap of $13M.
As of today, Akari Therapeutics’s PE (Price to Earnings) ratio is —.
View the latest Akari Therapeutics insider transactions to see recent buying and selling activity by company executives and directors.
Check the Akari Therapeutics congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The AKTX stock price chart above shows Akari Therapeutics’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Akari Therapeutics technical analysis for RSI, moving averages, and more.
See the stocks similar to Akari Therapeutics section on this page for companies in the same industry ranked by market cap and AI Score.
